Welcome to our dedicated page for APTOF SEC filings (Ticker: APTOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aptose Biosciences Inc. (APTOF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Canadian issuer reporting to the U.S. Securities and Exchange Commission. Aptose files current reports on Form 8-K under Commission File Number 001-32001, alongside its Canadian securities filings. These documents are central for investors who want to understand the company’s clinical-stage oncology business, financial condition, and pending corporate transactions.
For Aptose, Form 8-K filings are particularly important. Recent 8-Ks include Regulation FD disclosures that furnish press releases about tuspetinib (TUS) clinical data from the TUSCANY Phase 1/2 trial, including safety, complete remission (CR/CRh) rates, and minimal residual disease (MRD) findings in acute myeloid leukemia (AML). Other 8-Ks report quarterly financial results, detailing research and development expenses by program, general and administrative costs, cash balances, and the company’s reliance on loan facilities from Hanmi Pharmaceutical Co. Ltd. to fund operations.
Another critical category of filings relates to material definitive agreements and corporate transactions. Aptose has filed an 8-K describing its definitive arrangement agreement with Hanmi and HS North America Ltd., under which a Hanmi subsidiary will acquire all Aptose common shares not already owned or controlled by Hanmi or its affiliates, subject to shareholder and court approvals. That filing outlines the transaction structure, consideration for minority shareholders, required approvals, and the expectation that, after completion, Aptose will no longer be subject to certain reporting requirements and its shares will be delisted from stock exchanges including the TSX.
Through Stock Titan, investors can review these filings and use AI-powered summaries to interpret key sections, such as risk factor discussions, forward-looking statements, and the implications of financing and transaction agreements. The platform also tracks new 8-Ks in real time, helping users monitor Aptose’s ongoing clinical disclosures, financial updates, and progress toward the proposed acquisition.
Aptose Biosciences Inc. is asking shareholders to approve its acquisition by HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical, via a court-approved plan of arrangement. Public shareholders would receive C$2.41 in cash per share, with Hanmi’s existing holdings excluded from the payout.
The deal requires a continuance of Aptose from the CBCA to the ABCA and special resolutions approving both the continuance and the arrangement, including a two‑thirds majority and a separate majority of disinterested shares under MI 61‑101. A special committee obtained a formal valuation from Locust Walk of C$1.00–C$5.08 per share and a fairness opinion supporting the cash consideration.
If completed, Aptose will become an indirect wholly owned subsidiary of Hanmi, its shares will be delisted from the TSX and OTC Markets, and it will cease to be a reporting issuer in Canada and under the U.S. Exchange Act. Registered shareholders have dissent rights to seek fair value, subject to strict procedures and deadlines, while failure to close in certain circumstances could lead to court‑supervised CCAA proceedings.
Aptose Biosciences Inc. plans to be acquired by HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical, for C$2.41 in cash per share. The deal will be completed through a court-approved plan of arrangement after Aptose continues from federal CBCA to Alberta’s ABCA.
Independent advisor Locust Walk valued Aptose shares in a range of C$1.00 to C$5.08 and concluded the C$2.41 cash consideration is fair from a financial point of view to minority shareholders. Aptose’s board and a special transaction committee unanimously recommend voting FOR the continuance and arrangement resolutions.
The transaction requires at least 66⅔% shareholder approval for both resolutions, plus a simple majority of disinterested votes on the arrangement. If completed, Aptose will become an indirect wholly owned subsidiary of Hanmi, its shares will be delisted from the TSX and OTC Markets, and it will cease to be a reporting issuer. If the arrangement fails in specified circumstances, Aptose may be required to pursue alternative restructuring under Canada’s CCAA and pay a C$300,000 expense fee in some break scenarios.
Aptose Biosciences is asking shareholders to approve a cash acquisition by HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical, through a statutory plan of arrangement under Alberta corporate law.
If completed, public shareholders (other than Hanmi and its affiliates) will receive C$2.41 in cash per share, and Aptose will become an indirect wholly owned subsidiary of Hanmi, with its shares delisted from the TSX and OTC Markets and deregistered under U.S. and Canadian securities laws. An independent committee obtained a formal valuation from Locust Walk indicating a fair value range of C$1.00 to C$5.08 per share and a fairness opinion that the C$2.41 cash consideration is financially fair to minority shareholders.
The deal requires a continuance from the CBCA to the ABCA and approval of both a Continuance Resolution and an Arrangement Resolution, each needing at least 66⅔% of votes cast, plus a separate majority of minority approval for the Arrangement. If the transaction is not completed, the company warns of potential material pressure on the share price and, in certain cases, a requirement to pursue court-supervised restructuring under Canada’s CCAA.
Aptose Biosciences Inc. filed a current report on Form 8-K to furnish information under Regulation FD. On December 19, 2025, the company issued a press release, which is attached as Exhibit 99.1 and incorporated by reference. The company specifies that, under General Instruction B.2, the press release is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other securities filings unless specifically referenced.
Aptose Biosciences Inc. filed a current report to furnish information under Regulation FD. The company states that on December 6, 2025, it issued a press release, which is attached as Exhibit 99.1 to this report and incorporated by reference.
The press release is being provided under Item 7.01 (Regulation FD Disclosure) and, consistent with the stated instructions, is treated as “furnished” rather than “filed” for purposes of the Exchange Act and the Securities Act, unless later specifically incorporated by reference.
Aptose Biosciences Inc. agreed to be acquired by Hanmi Pharmaceuticals through a court-approved plan of arrangement. Hanmi’s subsidiary will purchase all Aptose common shares it does not already own for C$2.41 in cash per share, a 28% premium to Aptose’s 30‑day VWAP of C$1.88 on the TSX. The deal requires Aptose to first continue under the Business Corporations Act (Alberta), then complete the arrangement.
Closing is subject to court approval and shareholder approvals, including at least two‑thirds of votes cast and a separate majority of minority shareholders under MI 61‑101. Aptose’s board, following a special committee’s unanimous recommendation and external advice, unanimously determined the transaction is in the company’s best interests. Directors and officers signed voting support agreements. After completion, Aptose expects its shares to be delisted from all exchanges and it will cease to be a reporting issuer. An expense fee of C$300,000 is payable to Hanmi’s subsidiary if the agreement is terminated in certain circumstances.
Aptose Biosciences Inc. filed a current report to furnish a company press release under Regulation FD. The filing states that a press release dated November 19, 2025 is attached as Exhibit 99.1 and is incorporated by reference, but is treated as “furnished” rather than “filed” for liability purposes.
Aptose Biosciences Inc. filed its Q3 2025 report, highlighting ongoing development of tuspetinib while facing significant financial strain. The company reported a net loss of $5.1 million for the quarter and $17.7 million for the nine months. Cash, cash equivalents and restricted cash were $1.6 million as of September 30, 2025, with cash used in operations of $16.1 million year‑to‑date. Management states that conditions raise substantial doubt about the Company’s ability to continue as a going concern.
To fund operations, Aptose relied on related‑party facilities with Hanmi: an $8.5 million facility fully drawn and an additional up to $11.9 million facility, of which $4.2 million was advanced by October 27, 2025. Loan payable to related party rose to $18.7 million. Shareholders’ deficit widened to $(19.5) million. The company effected a 1‑for‑30 reverse stock split on February 26, 2025 and used an ATM to raise $1.0 million gross. 2,552,429 common shares were outstanding as of November 7, 2025.
Aptose Biosciences Inc. filed a Form 8-K to furnish a press release covering its results of operations and financial condition. The press release, dated November 13, 2025, is attached as Exhibit 99.1 and is incorporated by reference for informational purposes.
The company states that the Exhibit 99.1 information is being furnished under the Exchange Act and will not be deemed filed under Section 18, nor automatically incorporated into Securities Act or Exchange Act filings unless specifically referenced.
Aptose Biosciences Inc. furnished a press release under Item 7.01 (Regulation FD) via a Form 8-K. The release is attached as Exhibit 99.1 and incorporated by reference in this report.
Consistent with General Instruction B.2, the Item 7.01 information is deemed furnished, not filed, and is not incorporated by reference into Securities Act or Exchange Act filings unless expressly stated by specific reference.